Forum Archive Index - May 2002

[nickk@quicksilver.net.nz]

I think the sales figures at the bottom are askew.

It should read US$1 billion.

Cheers

Nk

G Stolwyk writes:

> 14-MAY-2002 TUE 09: 15 STEPHEN KWIK FAX NO. 98897607
> D2E7 - RECEIPT OF FIRST MILESTONE PAYMENT FROM ABBOlT
> On April 9 2002, Abbott Laboratories announced that it had submitted a 
>Biologic License
> Application to the US Food and Drug Administration and a Marketing 
>Authorisation
> Application to the European Agency for the Evaluation of Medicinal Products 
>seeking
> approval to market D2E7 for rheumatoid arthritis. Peptech has previously 
>informed the ASX
> that its TNF antibody patent is licensed to Knoll AG, which was acquired by 
>Abbott in March,
> 2001. Under the license agreement, Peptech was due to receive a milestone 
>payment upon
> the above submission.
> This announcement confirms the receipt of that milestone payment.
> Peptech's ManaginQ Director, Stephen Kwik. commented "We can look forward to 
>the receipt
> of two more milestone payments one due upon approval from the MAA in Europe 
>and the
> second upon first commercial shipment. Abbott has recently forecasted peak 
>sales of US51
> billion with sales expected to commence in 2003".
> Dr Paul Schober
> Investor Relations
> 14 May 2002
> 

----------------------------------------------------------------------------
To remove yourself from this list, please use the form at
http://www.sharechat.co.nz/chat/forum/